Sampling is naso-pharyngeal, saliva and it is not necessary to go on an empty stomach.

Molecular method based on the detection of SARS-CoV-2 virus RNA by RT-PCR. At present it is the reference technique for the diagnosis of the SARS-CoV-2 virus in the early stages of the disease. The molecular detection of the SARS-CoV-2 virus is very specific, therefore a positive confirms the detection of the virus.

A negative result does not always mean the absence of the virus as it depends on the viral load of the sample. If a negative result is obtained from a patient with a high suspicion of infection with the SARS-CoV-2 virus, it should be confirmed with a new test.

Detection of IgM and IgG antibodies against COVID-2019 (SARS-CoV-2) by means of the reference test (ELISA / Chemiluminescence): quantitative immunoassay with CE marking.

The COVID-19 antibody test looks for antibodies in your blood. This test measures whether you have had the virus in the past. This test has almost 100 % accurate sensitivity and specificity to SARS-CoV-2.

The test will be done via a blood sample. It is worth mentioning that the IgM and IgG antibody detection test against COVID-19 through the immunoassay is NOT the rapid test or rapid antibody detection test.

IgM type antibodies are markers of recent infection and are detected in 90% of cases between days 4 to 7 of infection, continue to increase until day 14 and then begin to decrease.

IgG antibodies are detected somewhat later (on average on day 8 post infection), and increase up to approximately 3 weeks.

Rapid tests, sampling is naso-pharyngeal, saliva and it is not necessary to go on an empty stomach. 

This test has the advantage that in a short time you get the result, with a high sensitivity at the beginning of the coronavirus infection.

When the contagion has occurred more than 7 days ago, the test loses effectiveness, giving false negatives and it does not exclude that the patient has overcome the disease and still has virus particles.